

# Clinical Criteria, Step Therapy, and Quantity Limits for TennCare Preferred Drug List (PDL): Acute Use Up to 15-Day Supply Opioid Criteria

July 1, 2018

On January 16, 2018 TennCare implemented an edit on agents in the Short-Acting and Long-Acting Narcotics classes of the PDL that was applied to all first-time and non-chronic opioid users. **Effective July 1, 2018, TennCare adjusted the maximum allowed morphine milligram equivalents (MME) daily dosage as follows:**

- A member can receive opioid prescription coverage for up to 15 days in a 180-day period at a maximum dosage of **60 MME per day**
  - All first-fill scripts in a 180-day period will be limited to a 5-day quantity of a short-acting opioid at a maximum dose of **60 MME per day** without the need for prior authorization (PA)
  - After the first-fill prescription, a member can receive up to an additional 10-day quantity of opioid treatment at a maximum dose of **60 MME per day** in each 180-day period with prior authorization

Acute Use Up to 15-Day Supply Opioid Criteria	
<p><b>Prior Authorization Criteria</b></p> <p><b>*Note: Prior Authorization criteria found at the following web link will also remain in effect:</b>  <a href="https://tenncare.magellanhealth.com/static/docs/Preferred_Drug_List_and_Drug_Criteria/Criteria_PDL.pdf">https://tenncare.magellanhealth.com/static/docs/Preferred_Drug_List_and_Drug_Criteria/Criteria_PDL.pdf</a></p>	<p><b>PA Form</b></p>
<p>PA criteria for acute users denying for “Additional quantities for acute use require prior authorization”: (approval will allow up to 10-day quantity not to exceed 60 MME/day; not to exceed 15 days’ supply per 180 days)</p> <p>Will be approved for recipients who meet ALL of the following criteria</p> <ul style="list-style-type: none"> <li>• Diagnosis of moderate-severe pain; <b>AND</b></li> <li>• The prescriber has assessed the member using a Screening, Brief Intervention, And Referral to Treatment (SBIRT) Questionnaire (e.g., SBIRT Survey) (for pts &gt;18 years of age) or using an adolescent Screening, Brief Intervention, and Referral to Treatment (SBIRT) Questionnaire (e.g., SBIRT CRAFFT Survey) (for pts 11-18 years of age)</li> <li>• Patient is not currently undergoing active treatment for opioid addiction; <b>AND</b></li> <li>• Female of childbearing age (14-44 years):               <ul style="list-style-type: none"> <li>– Is not pregnant; <b>AND</b></li> <li>– Using contraception (e.g. barrier, oral contraceptive, rhythm method); <b>OR</b></li> <li>– Has an intrauterine device (IUD) or implant; <b>OR</b></li> <li>– Has history of hysterectomy, tubal ligation, or endometrial ablation; <b>AND</b></li> </ul> </li> <li>• Concomitant use of benzodiazepines and opioids will only be approved under the care of, or referral to, a mental health provider.</li> </ul> <p><b>Note:</b> Use of opioid analgesics during pregnancy has been associated with Neonatal Abstinence Syndrome. Providers <b>MUST</b> counsel women of childbearing age regarding the risks of becoming pregnant while receiving opioids, including the risk of Neonatal Abstinence. Providers should offer access to effective contraceptive services when necessary.</p>	<p><a href="#">Acute Opioid PA Form</a></p>